EP Patent

EP1819353B1 — Composition for proteasome inhibition

Assigned to Onyx Therapeutics Inc · Expires 2011-02-23 · 15y expired

What this patent protects

Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comp…

USPTO Abstract

Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed:

Drugs covered by this patent

Patent Metadata

Patent number
EP1819353B1
Jurisdiction
EP
Classification
—
Expires
2011-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Onyx Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.